

CD40 Protein, Human, Recombinant (aa 21-193, His & Avi), Biotinylated

General Information

Synonyms:	CD40 antigen; TNFRSF5;CD40 molecule;CD40;MGC9013;CD40L receptor;CDw40
Protein Construction:	Glu21-Arg193
Species:	Human
Expression Host:	HEK293 Cells
Accession:	P25942
Molecular Weight:	22.1 kDa (predicted). Due to glycosylation, the protein migrates to 35-40 kDa based on Tris-Bis PAGE result.

QC Testing

Biological Activity:	Immobilized Anti-CD40 Antibody at 1µg/ml (100µl/well) on the plate. Dose response curve for Biotinylated Human CD40, His Tag with the EC50 of 31.3ng/ml determined by ELISA.
Purity:	> 95% as determined by Tris-Bis PAGE; > 95% as determined by HPLC
Endotoxin:	< 1.0 EU/µg of the protein as determined by the LAL method.
Formulation:	Lyophilized from a solution filtered through a 0.22 µm filter, containing PBS (pH 7.4). Typically, 8% trehalose is incorporated as a protective agent before lyophilization.

Preparation and Storage

Reconstitution:

Reconstitute the lyophilized protein in distilled water. The product concentration should not be less than 100 µg/ml. Before opening, centrifuge the tube to collect powder at the bottom. After adding the reconstitution buffer, avoid vortexing or pipetting for mixing.

Stability & Storage:

It is recommended to store recombinant proteins at -20°C to -80°C for future use. Lyophilized powders can be stably stored for over 12 months, while liquid products can be stored for 6-12 months at -80°C. For reconstituted protein solutions, the solution can be stored at -20°C to -80°C for at least 3 months. Please avoid multiple freeze-thaw cycles and store products in aliquots.

Actual storage temperature shall be subject to the COA.

Shipping:

In general, lyophilized powders are shipped with blue ice, while solutions are shipped with dry ice.

Protein Background

CD40 is a costimulatory protein found on antigen presenting cells and is required for their activation. The binding of CD154 (CD40L) on TH cells to CD40 activates antigen presenting cells and induces a variety of downstream effects. CD40 molecule is a potential target for cancer immunotherapy. There are number of completed and ongoing clinical trials where agonistic anti-CD40 monoclonal antibodies are employed to activate an anti-tumor T cell response via activation of dendritic cells.

Reference

Pound, J. D. Minimal cross-linking and epitope requirements for CD40-dependent suppression of apoptosis contrast with those for promotion of the cell cycle and homotypic adhesions in human B cells[J]. International Immunology, 1999, 11(1):11-20

Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins

This product is for Research Use Only · Not for Human or Veterinary or Therapeutic Use

Tel:781-999-4286 E_mail:info@targetmol.com Address:34 Washington Street,Wellesley Hills,MA 02481